Yury Morozov | Neuroscience | Innovative Research Award

Innovative Research Award

Yury Morozov
Yale School of Medicine, Department of Neuroscience, United States

Yury Morozov
Affiliation Yale School of Medicine, Department of Neuroscience
Country United States
Scopus ID 12243546400
Documents 47
Citations 3,747
h-index 28
Subject Area Neuroscience
Event World Cell Biologist Awards
ORCID 0000-0002-3679-6819

Yury Morozov is a researcher affiliated with the Department of Neuroscience at Yale School of Medicine in the United States. His academic profile is associated with neuroscience research and scholarly contributions reflected in indexed publication and citation records. According to the supplied bibliometric information, his research portfolio comprises 47 documents, 3,747 citations, and an h-index of 28. His profile is presented in connection with the Innovative Research Award of the World Cell Biologist Awards, recognizing research contributions and their relevance to the broader scientific community. [1]

Abstract

This academic recognition profile presents the research background and bibliometric information of Yury Morozov, affiliated with the Department of Neuroscience at Yale School of Medicine, United States. His scholarly record includes 47 indexed documents, 3,747 citations, and an h-index of 28, according to the information supplied for this profile. The article outlines his institutional affiliation, research domain, publication record, scholarly visibility, and relevance to the Innovative Research Award presented by the World Cell Biologist Awards. The profile provides an overview of research recognition within the wider context of neuroscience and biomedical investigation. [1] [2]

Keywords

Yury Morozov; Innovative Research Award; Neuroscience; Yale School of Medicine; Department of Neuroscience; Biomedical Research; Scientific Publications; Research Impact; Citation Analysis; Academic Recognition; World Cell Biologist Awards.

Introduction

Neuroscience is an interdisciplinary scientific field concerned with the structure, function, development, and organization of the nervous system. It integrates molecular biology, cellular biology, physiology, genetics, computational methods, and clinical investigation to understand neural processes and their implications for health and disease. Research in this area contributes to the development of scientific knowledge concerning brain function, neural communication, and neurological conditions. [1] [3]

Research Profile

Yury Morozov’s academic affiliation is the Department of Neuroscience at Yale School of Medicine. His stated subject area is neuroscience, a broad discipline encompassing the study of nervous system organization, neural development, cellular processes, and functional mechanisms. Institutional affiliation and indexed author information provide a framework for identifying scholarly contributions and examining research activity across publications. [2] [3]

Research Contributions

Research contributions in neuroscience can span multiple levels of biological organization, from molecular and cellular mechanisms to neural circuits and integrated nervous system functions. The field depends on experimental approaches, quantitative analysis, and interdisciplinary collaboration to investigate complex biological questions. [2]

Publications

The supplied Scopus profile information reports 47 documents associated with Yury Morozov. Publication records provide an important basis for evaluating research activity, scholarly collaboration, and the dissemination of scientific findings. The Scopus author profile is the principal reference point for examining the indexed publication list and associated citation information. [5]

Research Impact

Research impact can be assessed through several complementary indicators, including publication output, citation activity, scholarly collaboration, methodological contributions, and the influence of research findings on subsequent investigations. Citation metrics provide quantitative evidence of how frequently indexed publications are cited within scholarly literature, but they should not be treated as a complete measure of scientific quality or societal impact.

The supplied profile reports 3,747 citations and an h-index of 28 across 47 documents. The h-index represents a relationship between publication output and citation frequency, indicating that at least 28 publications have received 28 or more citations, provided the figures correspond to the same database snapshot and author record. These indicators offer a quantitative overview of scholarly visibility in the indexed literature. [4]

Award Suitability

The Innovative Research Award of the World Cell Biologist Awards is associated with the recognition of research activity, scientific contributions, and innovation across relevant biomedical and life science disciplines. Neuroscience represents an important research domain within biomedical science, with connections to cellular mechanisms, molecular processes, neural function, and neurological investigation.

Yury Morozov’s supplied academic profile identifies his institutional affiliation, subject area, publication output, and citation indicators. These details provide relevant background for an academic recognition profile. A complete award assessment should additionally examine the originality of specific research findings, documented contributions, publication quality, and the candidate’s demonstrated influence within the relevant scientific field. [4]

Conclusion

Yury Morozov’s academic profile reflects an association with the Department of Neuroscience at Yale School of Medicine in the United States. The supplied bibliometric information records 47 documents, 3,747 citations, and an h-index of 28 in the subject area of neuroscience. These indicators provide a quantitative overview of his indexed scholarly activity and form part of the academic information presented in connection with the Innovative Research Award of the World Cell Biologist Awards. [3]

References

  1. Elsevier. (n.d.). Scopus author details: Yury Morozov, Author ID 12243546400. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=12243546400
  2. K Pattabiraman, SK Muchnik, N Kaur, YM Morozov, et al. (2021). Hominini-specific regulation of CBLN2 increases prefrontal spinogenesis.
    https://www.nature.com/articles/s41586-021-03952-y
  3. SN Leslie, M Wang, YM Morozov, et al. (2021). Age‐related calcium dysregulation linked with tau pathology and impaired cognition in non‐human primates.
    https://alz-journals.onlinelibrary.wiley.com/doi/abs/10.1002/alz.12325
  4. D Franjic, M Skarica, S Ma, YM Morozov, et al. (2022). Transcriptomic taxonomy and neurogenic trajectories of adult human, macaque, and pig hippocampal and entorhinal cells.
    https://medicine.yale.edu/
  5. VC Galvin, J Solder, F Luo, YM Morozov, et al. (2019). Noradrenergic α1-adrenoceptor actions in the primate dorsolateral prefrontal cortex.
    https://www.jneurosci.org/content/39/14/2722.abstract

Jeongseop Kim | Neuroscience | Research Excellence Award

Prof. Dr. Jeongseop Kim | Neuroscience | Research Excellence Award

Daegu Catholic University School of Medicine/Department of Pharmacology | South Korea

The research focuses on elucidating molecular, epigenetic, and neural circuit mechanisms underlying emotional and cognitive disorders. Key areas include identifying epigenetic modifications associated with behavioral changes in mood disorders, uncovering neural circuit and molecular pathways involved in treatment-resistant depression, and examining neural network mechanisms that regulate motivational behaviors such as reward processing, addiction, sexual behavior, and decision-making. Using an integrative approach combining behavioral neuroscience, molecular pharmacology, and systems and computational neuroscience, the work aims to clarify how chronic stress alters brain function and how resilience or anhedonia emerges, ultimately contributing to the development of novel therapeutic strategies for neuropsychiatric diseases.

Featured Publications

Abdelhamid Benazzouz | Neuronal Cell Biology | Best Researcher Award

Prof. Abdelhamid Benazzouz | Neuronal Cell Biology | Best Researcher Award

Bordeaux University / Neurodegenerative Diseases Institute | France

Dr. Abdelhamid Benazzouz is a distinguished neuroscientist whose pioneering research has significantly advanced understanding and treatment of Parkinson’s disease. His groundbreaking work during his Ph.D. led to the development of deep brain stimulation (DBS) of the subthalamic nucleus as a novel therapeutic approach for Parkinson’s disease, which was later translated into clinical application. His research focuses on elucidating the mechanisms of action of DBS, exploring the role of monoaminergic systems in the pathophysiology of Parkinson’s disease, and investigating pain mechanisms associated with the disorder. He has led numerous national and international research projects funded by organizations such as the Agence Nationale de la Recherche, Fondation pour la Recherche Médicale, and the Michael J. Fox Foundation. With over 120 publications, more than 24,000 citations, and multiple patents, his contributions span both basic and translational neuroscience. He also leads collaborative research efforts across France, the Netherlands, and Hong Kong to develop innovative therapeutic strategies. As Editor-in-Chief and founder of the Elsevier journal Deep Brain Stimulation, he continues to influence the global neuroscience community, driving forward advancements in neurostimulation, monoaminergic signaling, and the treatment of neurological disorders, particularly Parkinson’s disease and related pain syndromes.

Profiles: Google Scholar | Orcid

Featured Publications:

Krack, P., Batir, A., Van Blercom, N., Chabardes, S., Fraix, V., Ardouin, C., … & Benabid, A. L. (2003). Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. The New England Journal of Medicine, 349(20), 1925–1934.

Limousin, P., Krack, P., Pollak, P., Benazzouz, A. H., Ardouin, C., Hoffmann, D., … & Benabid, A. L. (1998). Electrical stimulation of the subthalamic nucleus in advanced Parkinson’s disease. The New England Journal of Medicine, 339(16), 1105–1111.

Limousin, P., Pollak, P., Benazzouz, A., Hoffmann, D., Le Bas, J. F., Perret, J. E., … & Benabid, A. L. (1995). Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. The Lancet, 345(8942), 91–95.

Benabid, A. L., Pollak, P., Gao, D., Hoffmann, D., Limousin, P., Gay, E., Payen, I., & Benazzouz, A. (1996). Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. Journal of Neurosurgery, 84(2), 203–214. Benazzouz, A., Gross, C., Féger, J., Boraud, T., & Bioulac, B. (1993). Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. European Journal of Neuroscience, 5(4), 382–389.

Krack, P., Pollak, P., Limousin, P., Hoffmann, D., Xie, J., Benazzouz, A., … & Benabid, A. L. (1998). Subthalamic nucleus or internal pallidal stimulation in young-onset Parkinson’s disease. Brain: A Journal of Neurology, 121(3), 451–457.

Benabid, A. L., Pollak, P., Gross, C., Hoffmann, D., Benazzouz, A., Gao, D. M., … & Perret, J. (1994). Acute and long-term effects of subthalamic nucleus stimulation in Parkinson’s disease. Stereotactic and Functional Neurosurgery, 62(1–4), 76–84.

Carlos Cruchaga | Neuronal Cell Biology | Best Researcher Award

Dr. Carlos Cruchaga | Neuronal Cell Biology | Best Researcher Award

Dr. Carlos Cruchaga, Washington Univeristy, United States

Dr. Carlos Cruchaga is a tenured Professor at Washington University School of Medicine, with joint appointments in Psychiatry, Genetics, and Neurology. He is the Director of the NeuroGenomics and Informatics Center and leads multiple high-impact cores including the Knight ADRC, DIAN Genetics Core, and Biorepository Core for initiatives like the Dystonia Coalition and Aging Adult Brain Connectome. Internationally recognized for his pioneering work in neurodegenerative diseases, Dr. Cruchaga specializes in integrating multi-omic datasets to identify novel genetic and molecular mechanisms underlying Alzheimer’s disease and other neurological disorders. He has authored over 340 peer-reviewed publications and continues to lead major NIH-funded projects. With a strong commitment to translational research, he also contributes to tool development for omics data analysis. His work consistently bridges the gap between basic research and clinical application, making him a deserving candidate for the Best Researcher Award.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  • Leadership: Director of NeuroGenomics and Informatics Center; leads major genetics cores (Knight ADRC, DIAN, Dystonia Coalition, AABC).

  • Research Impact: Over 346 peer-reviewed publications with significant contributions in Alzheimer’s Disease (AD), neurodegeneration, multi-omics, and genetic epidemiology.

  • Translational Focus: Discoveries such as rare variants in AD-related genes (APP, PSEN1, PSEN2, PLD3, TREM2) and biomarker identification have major clinical implications.

  • Global Collaborations: Works with international research consortia including ADNI, GERAD, and Alzheimer’s Research UK, showing both scientific influence and collaboration.

  • Recognition: Invited speaker at high-level conferences; selected for the prestigious Spanish “Excellence Campus 2005”.

  • Innovation: Pioneered multi-omic and bioinformatic pipelines for biomarker discovery.

⚠️ Areas for Improvement:

  • Public Outreach: While academically exceptional, public or patient-facing outreach or science communication isn’t highlighted.

  • Diversity Initiatives: Potential to expand into mentorship programs or initiatives focused on increasing diversity in genomics.

  • Commercialization: There is room to emphasize translational science through startups, patents, or technology transfer.

🎓 Education:

Dr. Cruchaga earned his undergraduate degree in Biochemistry from the University of Navarra, Pamplona, Spain (1996–2000). He continued his graduate studies at the same institution, obtaining an MA (2000–2002) followed by a PhD in Biochemistry and Molecular Biology in 2005. His doctoral research, awarded Summa Cum Laude, focused on molecular mechanisms and biomarkers associated with neurodegenerative diseases. Dr. Cruchaga was selected among Spain’s top 18 PhD students to present his research at the “Excellence Campus 2005,” hosted by the Spanish Government and attended by Nobel Laureates. His training included foundational roles as a student and teaching assistant in the Department of Biochemistry and Molecular Biology, setting the stage for a career deeply rooted in research excellence and academic mentorship. This strong academic background has been instrumental in shaping his translational approach to complex neurological conditions like Alzheimer’s and dystonia.

💼 Experience:

Dr. Cruchaga has amassed extensive experience across academic, administrative, and research leadership roles. Since 2019, he has served as a Professor in Psychiatry, Genetics, and Neurology at Washington University. He is also the current Director of the NeuroGenomics and Informatics Center (since 2018), where he supervises multi-disciplinary teams and oversees high-throughput genomics operations. He leads cores in major initiatives such as the Knight Alzheimer’s Disease Research Center (ADRC), DIAN (Dominantly Inherited Alzheimer Network), and the Dystonia Coalition. Earlier roles include serving on the Alzheimer’s Association International Conference Scientific Program Committee (2014–2017), where he curated session topics, evaluated hundreds of abstracts, and chaired sessions. His international collaborations span omics, imaging, and computational biology, making him a leader in neurogenomics. These diverse roles have allowed Dr. Cruchaga to influence both scientific innovation and strategic planning within global neuroscience research initiatives.

🏅 Honors and Awards:

Dr. Cruchaga’s excellence has been recognized through numerous awards and invitations. In 2005, he was chosen for “Excellence Campus 2005,” a prestigious event featuring the top Spanish PhD students alongside Nobel Prize winners. He has received multiple invitations for keynote lectures and seminars at institutions across Europe and the U.S., including the University of the Basque Country, the Center for Applied Medical Research in Pamplona, and Washington University. He was a finalist for the O’Leary Award for Research in Neuroscience in 2009. His service as a Scientific Program Committee Member for the Alzheimer’s Association International Conference further underscores his leadership in the field. These accolades not only celebrate his scientific contributions but also affirm his status as a thought leader in neurodegenerative disease research. His peer-reviewed work has appeared in top-tier journals like Nature, Neuron, and Acta Neuropathologica.

🔬 Research Focus:

Dr. Cruchaga’s research centers on understanding the molecular and genetic underpinnings of neurodegenerative diseases, particularly Alzheimer’s disease, using integrative multi-omics approaches. His lab specializes in analyzing genomic, transcriptomic, proteomic, and metabolomic data from human biospecimens to uncover biomarkers, risk variants, and causal pathways. He has led groundbreaking studies identifying rare coding variants in genes like TREM2, PLD3, and APP, linking them to Alzheimer’s pathology. He applies advanced computational tools and machine learning to interpret high-dimensional data and translate findings into diagnostic and therapeutic strategies. As director of several national consortia cores (e.g., Knight ADRC, DIAN), he facilitates data-sharing and harmonization across global cohorts. His work also explores the genetic architecture of disorders like dystonia and peripheral neuropathy. The long-term goal of his research is to bridge omics data with clinical outcomes to enable personalized medicine in neurology.

📚 Publications Top Notes:

  1. 🧠 Rare variants in APP, PSEN1 and PSEN2 increase AD risk in late-onset families – PLoS One (2012)

  2. 🧬 GWAS of CSF tau levels reveals novel AD risk variants – Neuron (2013)

  3. 🧠 Rare coding variants in PLD3 gene confer AD risk – Nature (2014)

  4. 🧠 TREM2 coding variants increase AD risk – Human Molecular Genetics (2014)

  5. 🧪 TREM2 variants linked to AD risk in African Americans – Mol Neurodegeneration (2015)

  6. 🧫 Higher CSF soluble TREM2 linked to AD mutation status – Acta Neuropathologica (2016)

  7. 🧪 Genetics of plasma analytes identifies novel biomarkers – Scientific Reports (2016)

  8. 🧬 Variants in Mendelian AD genes within ADSP – JAD (2025)

  9. 🧠 RFC1 AAGGG repeat expansions common in neuropathy – Preprint (2025)

  10. 🧪 Plasma proteomics uncovers novel AD biomarkers – Preprint (2025)

🧾 Conclusion:

Dr. Carlos Cruchaga exemplifies the highest standards of neuroscience and genomics research. His contributions have advanced the global understanding of Alzheimer’s disease, making him a top-tier candidate for the Best Researcher Award. His scientific leadership, prolific output, and translational success position him as a standout in the biomedical field.